Corticosteroids: Options in the era of steroid-sparing therapy - 21/08/11
Las Vegas, Nevada, and San Diego, California
Abstract |
Topical corticosteroids remain the most commonly used topical treatments for inflammatory dermatoses, including psoriasis and atopic dermatitis. Topical corticosteroids are available in a variety of vehicles—creams, ointments, lotions, gels, and, more recently, foam. The vehicle used can substantially affect the individual agent's clinical action, potency, and acceptability to the patient. Moreover, some vehicles are better suited for specific body areas. Selection of the appropriate product should be determined by area of usage, physician experience, cost, and patient preference, particularly regarding vehicle. Although topical corticosteroids are associated with several side effects, including skin atrophy, telangiectases, purpura, and striae formation, appropriate usage can minimize these occurrences. Judicious use includes short-term, appropriate application as initial monotherapy or in combination strategies with other therapeutic agents that ideally possess complementing mechanisms of action. Examples include pulsing with high-potency topical corticosteroids and combination regimens with other topical agents such as topical calcineurin inhibitors, calcipotriene, or tazarotene. Appropriate education of patients and caregivers alike will facilitate the optimal use of these medications.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AD, BMV, HPA, TCI
Plan
This article is part of a supplement supported by Connetics Corp, Palo Alto, California. Disclosure: Dr Del Rosso serves (or has served) as a consultant to Allergan, Berlex, CollaGenex, Connetics Corp, Dermik, Galderma, Healthpoint, Medicis, Novartis; and Stiefel; and as a speaker for all the aforementioned companies. Dr Friedlander has no financial interest in the products discussed in this review. She has performed clinical trials or consulted for Novartis, Fujisawa, Connetics Corp, Schering, and GlaxoSmithKline Pharmaceuticals. |
Vol 53 - N° 1S
P. S50-S58 - juillet 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?